Lilly takes oral obesity race abroad with UK launch of Foundayo

Summary

Eli Lilly is expanding Foundayo's obesity treatment into international markets, with analyst commentary suggesting the UK launch positions the small-molecule drug competitively against Novo Nordisk's offerings due to favorable margin economics.